

[175] OFF-THE-SHELF, ENGINEERED GAMMA DELTA T-CELL THERAPIES

Stewart Abbot, Chief Operating Officer, Adicetbio, Menlo Park, United States

- **Investment Rational**

Adicet bio, Inc. (Adicet) is developing cutting-edge, off-the-shelf immunotherapies, employing allogeneic gamma delta ($\gamma\delta$) T cells engineered with chimeric antigen receptors (CARs) and T cell receptor-like (TCR-L) antibodies. These therapies have the potential to profoundly transform the treatment of cancer and other diseases.
- **Business Strategy**

Adicet's core focus is the development of next-generation off-the-shelf oncology immunotherapeutics. Adicet has a strategic alliance with Regeneron Pharmaceuticals for the development of $\gamma\delta$ T cell-based cancer therapies. Adicet intends to further partner to fully exploit the potential of $\gamma\delta$ T cells and TCR-L antibodies in infectious- and autoimmune diseases
- **Core Technology**

Adicet's core technologies include, i) the ability to selectively produce, potent off-the-shelf, populations of $\gamma\delta$ T cells, ii) a proprietary process to identify, and effectively target liquid and solid tumor antigens using TCR-L antibodies and iii) development of a robust, cost-effective, cGMP-compliant $\gamma\delta$ T cell manufacturing process. Adicet acquired TCR-L antibody capabilities via acquisition of Applied Immune Technologies (AIT, Haifa).
- **Product Profile/Pipeline**

Adicet's lead candidate is a $\gamma\delta$ T cell therapy engineered to express CD20 targeting CAR - termed ADI-001. ADI-001 is anticipated to enter clinical trials in the United States in 1H 2020. Our preclinical pipeline also contains a number of other CAR-modified $\gamma\delta$ T cell candidates targeting other hematologic and solid tumors
- **What's Next?**

2019 will be an exciting year for Adicet; we anticipate submitting an IND application for our first clinical candidate later this year and starting landmark clinical studies for CAR-modified allogeneic $\gamma\delta$ T cells in lymphoma shortly thereafter. Furthermore, we are rapidly developing our pipeline to include several candidates that are optimized to address the demands of effectively treating solid tumors.